

## American Society of Hematology Annual Meeting (ASH) 2019

Orange County Convention Center, Orlando, FL

December 7-10, 2019

### POSTER PRESENTATIONS

Authors	Title	Session #	Date/Time/ Location
Lynne I. Wagner, PhD1*, Kathleen Toomey, MD2*, Sikander Ailawadhi, MD3, Sundar Jagannath4*, Cristina Gasparetto, MD5, Brian G.M. Durie, MD6, <b>Mohit Narang, MD7*</b> , <b>Robert M. Rifkin, MD8</b> , Howard R. Terebelo, DO9, James L. Omel, MD10*, James W. Hardin, PhD11*, Hans C. Lee, MD12, Shankar Srinivasan, PhD, MBA13*, Liang Liu, MS13*, Mazaher Dhalla, PharmD13*, Donna Catamero, ANP-BC, OCN, CCRC13* and Rafat Abonour, MD14	1843 Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect® MM Registry <a href="https://ash.confex.com/ash/2019/webprogram/Paper126143.html">https://ash.confex.com/ash/2019/webprogram/Paper126143.html</a>	Session 653 USOR #9141	Saturday, December 7, 2019, 5:30 PM-7:30 PM  Hall B, Level 2 Orange County Convention Center
Roman Hajek, Prof, MD, PhD1, Jiri Minarik, MD, PhD2, Jan Straub, MD3*, Ludek Pour, MD4*, Alexandra Jungova5*, Jesus G. Berdeja, MD6, Mario Boccadoro, MD7, Lucie Brožová, MSc8*, Andrew Spencer, MBBS, FRACP, FRCPA, DM9, Frits van Rhee, MD, PhD10, Jorge Vela-Ojeda, MD, PhD11*, Michael A. Thompson, MD, PhD, FASCO12, Rafat Abonour, MD13,14, Ajai Chari, MD15, Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPATH16*, Caitlin L. Costello, MD17, Faith E. Davies, MD18, Vania T.M. Hungria, MD, PhD19, Hans C. Lee, MD20, Xavier Leleu, MD, PhD21, Noemi Puig, MD, PhD22*, <b>Robert M. Rifkin, MD23</b> , Evangelos Terpos, MD, PhD24, Saad Z. Usmani, MD, FACP25, Katja C. Weisel, MD26*, Jeffrey A. Zonder, MD27, Magda Bařinová, MSc28*, Matyáš Kuhn, MSc29*, Jiri Silar, MSc30*, Lenka Capkova31*, Kenny Galvez, MD32*, Jin Lu, MD/Prof33, Tomas Skacel, MD34,35*, Jennifer Elliott34*, Brittany Demers, BS, BA36*, Dawn Marie Stull, Pharm.D., BCOP34*, Kaili Ren, PhD34* and Vladimir Maisnar, MD, PhD, MBA37*	1845 Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study <a href="https://ash.confex.com/ash/2019/webprogram/Paper126606.html">https://ash.confex.com/ash/2019/webprogram/Paper126606.html</a>	Session 653 USOR #16035	Saturday, December 7, 2019, 5:30 PM-7:30 PM  Hall B, Level 2 Orange County Convention Center
<b>Robert M. Rifkin, MD1</b> , <b>Sudhir Manda, MD2,3</b> , Stephen J Noga, MD, PhD4, <b>Habte A Yimer, MD5</b> , Saulius K. Girnius, MD6, Ruemu Ejedafeta Birhiray, MD7, <b>Christopher A. Yasenachak, MD8</b> , <b>Roger M. Lyons, MD9</b> , Presley Whidden4*, Robert L. Schlossman, MD4, Bingxia Wang, PhD4* and Ralph V. Boccia, MD10	1882 Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting <a href="https://ash.confex.com/ash/2019/webprogram/Paper124747.html">https://ash.confex.com/ash/2019/webprogram/Paper124747.html</a>	Session 653 USOR #17081	Saturday, December 7, 2019, 5:30 PM-7:30 PM  Hall B, Level 2 Orange County Convention Center
<b>David Andorsky, MD1</b> , Rebecca J Chan, MD, PhD2, Jamiya Clark, MPH3*, Bianca Ruzicka, PhD2*, <b>Nicholas James Robert, MD3*</b> and Farrukh T. Awan, MD4	2810 Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting <a href="https://ash.confex.com/ash/2019/webprogram/Paper124013.html">https://ash.confex.com/ash/2019/webprogram/Paper124013.html</a>	Session 623	Sunday, December 8, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center

**Bolded text:** US Oncology Research affiliated investigator

\*Denotes non-member of the American Society of Hematology

**POSTER PRESENTATIONS**

Authors	Title	Session #	Date/Time/ Location
Anas Younes, MD1, <b>John M Burke, MD2</b> , Bruce D. Cheson, MD3, Catherine Diefenbach, MD4*, Silvia Ferrari, MD5*, Uwe H Hahn, MD6*, Eliza A Hawkes7*, Cyrus Khan, MD8, Izidore S. Lossos, MD9, Gerardo Musuraca, MD, PhD10*, Monica Tani11*, Umberto Vitolo, MD12, Sam Lung Sang Yuen, MBBS, FRCPA, FRACP13, Aparna Raval, PhD14*, Mahesh R. Shivhare, PhD15*, Tina G Nielsen, MD, PhD15*, Gila Sellam, PhD15* and <b>Jeff P. Sharman, MD2,16</b>	2874 Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study <a href="https://ash.confex.com/ash/2019/webprogram/Paper123368.html">https://ash.confex.com/ash/2019/webprogram/Paper123368.html</a>	Session 626 USOR #15054	Sunday, December 8, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center
<b>John M Burke, MD1</b> , Marc André2*, Bruce D. Cheson, MD3, Johannes Duell, MD4*, Grzegorz Nowakowski, MD5, Andreas Rosenwald, MD6*, Gilles A. Salles, MD, PhD7, <b>Jeff P. Sharman, MD8</b> , Philipp Bernhard Staber, MD, PhD9, Marek Trněný, MD10, Jason R. Westin, MD11, Wolfram Brugger12*, Günter Fingerle-Rowson, MD, PhD12,13, Magdalena Klanova12*, Guido Würth, PhD12* and Lorenz Truemper, MD14	2877 A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial <a href="https://ash.confex.com/ash/2019/webprogram/Paper128021.html">https://ash.confex.com/ash/2019/webprogram/Paper128021.html</a>	Session 626 USOR #19015	Sunday, December 8, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center
John N. Allan, MD1, Krish Patel, MD2, Anthony R. Mato, MD MSCE3, William G. Wierda, MD, PhD4, Javier Pinilla Ibarz, MD, PhD5, Michael Y. Choi, MD6, Susan M. O'Brien, MD7, <b>Jeff P. Sharman, MD8</b> , Mazyar Shadman, MD9, Douglas E Gladstone, MD10, Matthew S. Davids, MD11, John M. Pagel, MD, PhD, DSc2, Renee Ward, MD, PhD12*, Gary Acton, MD12*, Pietro Taverna, PhD12, Judith A. Fox, PhD12, Richard R. Furman, MD1 and Jennifer R Brown, MD, PhD13	3041 Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vencabrutinib, in B-Cell Malignancies <a href="https://ash.confex.com/ash/2019/webprogram/Paper126286.html">https://ash.confex.com/ash/2019/webprogram/Paper126286.html</a>	Session 642 USOR #17195	Sunday, December 8, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center
<b>Jeff P. Sharman, MD1</b> , David Andorsky, MD2, <b>Jason M. Melear, MD3</b> , <b>Sudhir Manda, MD4</b> , Bertrand M. Anz III, MD5*, <b>Kathryn S. Kolibaba, MD6</b> , <b>Habte A Yimer, MD7</b> , <b>John M Burke, MD8</b> , <b>Suzanne R. Fanning, DO9</b> , <b>Jay Courtright, MD10*</b> , <b>Miguel Islas-Ohlmayer, MD11*</b> , Suman Kambhampati, MD12*, Abdullah Al Masud, PhD13*, Todd Zimmerman14*, Jacqueline Nielsen, PhD15*, Tamas Vizkelety14*, Dingfeng Jiang13* and Ian W. Flinn, MD, PhD16	3042 Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study <a href="https://ash.confex.com/ash/2019/webprogram/Paper127408.html">https://ash.confex.com/ash/2019/webprogram/Paper127408.html</a>	Session 642 USOR #17106	Sunday, December 8, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center
Stephen J Noga, MD, PhD1, <b>Robert M. Rifkin, MD2</b> , <b>Sudhir Manda, MD3,4</b> , Ruemu Ejedafeta Birhiray, MD5, <b>Roger M. Lyons, MD6</b> , Presley Whidden1*, Robert L. Schlossman, MD1, Bingxia Wang, PhD1* and Ralph V. Boccia, MD7	3168 Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study <a href="https://ash.confex.com/ash/2019/webprogram/Paper124784.html">https://ash.confex.com/ash/2019/webprogram/Paper124784.html</a>	Session 653 USOR #17081	Sunday, December 8, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center
Alexey Danilov, MD, PhD1, <b>Habte A Yimer, MD2</b> , <b>Michael Boxer, MD3</b> , <b>John M Burke, MD4</b> , Sunil Babu, MD5*, Jia Li, PhD6, Yong Mun, PhD6*, Peter C Trask, PhD, MPH6*, Anthony S Masaquel, PhD, MPH6* and <b>Jeff P. Sharman, MD7</b>	3491 Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine <a href="https://ash.confex.com/ash/2019/webprogram/Paper123630.html">https://ash.confex.com/ash/2019/webprogram/Paper123630.html</a>	Session 905 USOR #13177	Sunday, December 8, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center

**Bolded text:** US Oncology Research affiliated investigator

\*Denotes non-member of the American Society of Hematology

**POSTER PRESENTATIONS**

Authors	Title	Session #	Date/Time/ Location
<b>Christopher A. Yasenachak, MD1</b> , Rodolfo Bordonì, MD2*, Victor Yazbeck, MD3, <b>Dipti Patel-Donnelly, MD4</b> , <b>Timothy Larson, MD5*</b> , Trevor Newhook, MS6*, Linda Ho6* and Matthew Mei, MD	2852 Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above <a href="https://ash.confex.com/ash/2019/webprogram/Paper122968.html">https://ash.confex.com/ash/2019/webprogram/Paper122968.html</a>	Session 624 USOR #11282	Sunday, December 8, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center
Aaron T. Gerds, MD, MS1, <b>Roger M. Lyons, MD2</b> , Philomena Colucci, DO, MS3*, Patricia Kalafut, PhD3*, Dilan Paranagama, PhD3* and Srđan Verstovsek, MD, PhD4	4190 Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study <a href="https://ash.confex.com/ash/2019/webprogram/Paper122441.html">https://ash.confex.com/ash/2019/webprogram/Paper122441.html</a>	Session 634 USOR #16092	Monday, December 9, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center
<b>Jeff P. Sharman, MD1</b> , <b>John M Burke, MD2</b> , <b>Habte A Yimer, MD3</b> , <b>Michael A. Boxer, MD4</b> , Sunil Babu, MD5*, Jia Li, PhD6, Yong Mun, PhD6* and Alexey Danilov, MD, PhD7	4317 Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia <a href="https://ash.confex.com/ash/2019/webprogram/Paper122482.html">https://ash.confex.com/ash/2019/webprogram/Paper122482.html</a>	Session 642 USOR #13177	Monday, December 9, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center
Bing-E Xu, PhD1*, Kristen M Rosenthal, PhD1*, Krista Marcello, BA1*, Farrukh T. Awan, MD2, Steven Coutre, MD3, Nicole Lamanna, MD4, <b>Jeff P. Sharman, MD5</b> , Timothy A Quill, PhD1*, Kevin L Obholz, PhD1* and Andrew D. Zelenetz, MD, PhD6	4724 Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia <a href="https://ash.confex.com/ash/2019/webprogram/Paper129266.html">https://ash.confex.com/ash/2019/webprogram/Paper129266.html</a>	Session 902	Monday, December 9, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center
Vania T.M. Hungria, MD, PhD1, Hans C. Lee, MD2, Rafat Abonour, MD3, <b>Robert M. Rifkin, MD4</b> , Evangelos Terpos, MD, PhD5, Xavier Leleu, MD, PhD6, Caitlin L. Costello, MD7, Frits van Rhee, MD, PhD8, Katja C. Weisel, MD9*, Noemi Puig, MD, PhD10*, Jesus G. Berdeja, MD11, Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPATH12*, Saad Z. Usmani, MD, FACP13, Michael A. Thompson, MD, PhD, FASCO14, Mario Boccadoro, MD15, Jeffrey A. Zonder, MD16, Andrew Spencer, MBBS, FRACP, FRCPA, DM17, Roman Hajek, Prof, MD, PhD18, Suzanne R. Fanning, DO19, Kevin Boyd, MB BS, BSc, MRCP, FRCPATH, PhD20*, Jim Omel, MD21*, Mira Armour, BSc22*, Kathryn E. Morgan23*, Ronak S. Patel24*, Gary L. Carlson25*, Renda H. Ferrari, PhD25*, Dawn Marie Stull, Pharm.D., BCOP25*, Kaili Ren, PhD25*, Dasha Cherepanov, PhD25*, James V. Pottala, PhD26* and Ajai Chari, MD27	1887 Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study <a href="https://ash.confex.com/ash/2019/webprogram/Paper125749.html">https://ash.confex.com/ash/2019/webprogram/Paper125749.html</a>	Session 653	Saturday, December 7, 2019, 5:30 PM-7:30 PM  Hall B, Level 2 Orange County Convention Center
<b>Michael Boxer, MD</b>	962 Iron Deficiency Anemia Caused by Malabsorption from Proton Pump Inhibition <a href="https://ash.confex.com/ash/2019/webprogram/Paper122154.html">https://ash.confex.com/ash/2019/webprogram/Paper122154.html</a>	Session 102	Saturday, December 7, 2019 5:30 PM-7:30 PM  Hall B, Level 2 Orange County Convention Center
Hans C. Lee, MD1, Sikander Ailawadhi, MD2, Cristina Gasparetto, MD3, Sundar Jagannath4*, <b>Robert M. Rifkin, MD5</b> , Brian G.M. Durie, MD6, Mohit Narang, MD7*, Howard R. Terebello, DO8, Kathleen Toomey, MD9*, James W. Hardin, PhD10*, Lynne I. Wagner, PhD11*, James L. Omel, MD12*, Shankar Srinivasan, PhD, MBA13*, Liang Liu, MS13*, Mazaher Dhalla, PharmD13*, Amit Agarwal, MD, PhD13 and Rafat Abonour, MD14	3129 Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect® MM Registry <a href="https://ash.confex.com/ash/2019/webprogram/Paper126205.html">https://ash.confex.com/ash/2019/webprogram/Paper126205.html</a>	Session 653	Sunday, December 8, 2019, 6:00 PM-8:00 PM  Hall B, Level 2 Orange County Convention Center

**Bolded text:** US Oncology Research affiliated investigator

\*Denotes non-member of the American Society of Hematology

## ORAL PRESENTATIONS

Authors	Title	Session #	Date/Time/ Location
<b>Christopher A. Yasenchak, MD1</b> , Rodolfo Bordoni, MD2*, Victor Yazbeck, MD3, <b>Dipti Patel-Donnelly, MD4</b> , <b>Thomas Anderson5*</b> , <b>Timothy Larson, MD6*</b> , Trevor Newhook, MS7*, Matthew Mei, MD8, Linda Ho7* and Jonathan W. Friedberg, MD9	0237 Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years Clinically Relevant Abstract <a href="https://ash.confex.com/ash/2019/webprogram/Paper124866.html">https://ash.confex.com/ash/2019/webprogram/Paper124866.html</a>	Session 624 USOR #11282	Saturday, December 7, 2019, 2:30 PM  W224, Level 2 Orange County Convention Center
Rachael M Andrie1*, <b>John M Burke, MD2</b> , Christopher R. Flowers, MD, MS3, Nathan H Fowler, MD4, <b>Jeff P. Sharman, MD5</b> , Timothy A Quill, PhD1*, Kevin L Obholz, PhD1* and Ian W. Flinn, MD, PhD6	0414 Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma <a href="https://ash.confex.com/ash/2019/webprogram/Paper128988.html">https://ash.confex.com/ash/2019/webprogram/Paper128988.html</a>	Session 902	Sunday, December 8, 2019, 10:45 AM  W307, Level 3 Orange County Convention Center
Madan Jagasia, MBBS, MS, MMHC1, Amandeep Salhotra, MD2, Carlos R. Bachier, MD3, Behyar Zoghi, MD, PhD, FACP4, Aleksandr Lazaryan, MD, PhD, MPH5, Daniel J. Weisdorf, MD6, <b>James Essell, MD7</b> , Laurie S. Green, MEd8*, Olivier Schueller, PhD8*, Lindy Huang8*, Zhongming Yang, PhD8*, David Eiznhamer, PhD8*, Sanjay K. Aggarwal, MD8*, Bruce R. Blazar, MD9 and Stephanie J. Lee, MD, MPH10	872KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) – Long-Term Follow-up of a Phase 2a Study (KD025-208) <a href="https://ash.confex.com/ash/2019/webprogram/Paper125986.html">https://ash.confex.com/ash/2019/webprogram/Paper125986.html</a>	Session 722	Monday, December 9, 2019, 4:45 PM  W230, Level 2 Orange County Convention Center
<b>Robert M. Rifkin, MD1</b> , <b>Jason M. Melear, MD2</b> , <b>Edward Faber, DO, MS3*</b> , William I. Bensinger4*, <b>John M Burke, MD5</b> , <b>Mohit Narang, MD6*</b> , Don Stevens, MD7, Sriya Gunawardena8*, Yana Lutska, PharmD8*, Keqin Qi, PhD9*, Jon Ukropec, PhD10, Ming Qi, MD, PhD11, Thomas S. Lin, MD, PhD8 and <b>Habte A Yimer, MD12</b>	0863 Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBORd) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study <a href="https://ash.confex.com/ash/2019/webprogram/Paper122497.html">https://ash.confex.com/ash/2019/webprogram/Paper122497.html</a>	Session 653 USOR #16084	Monday, December 9, 2019, 5:30 PM  Hall E2, Level 2 Orange County Convention Center
<b>Jeff P. Sharman, MD1</b> , Versha Banerji, MD2, Laura Maria Fogliatto, MD, PhD3, Yair Herishanu, MD4*, Talha Munir, MD5*, Renata Walewska6*, George Follows7*, Karin Karlsson, MD8*, Paolo Ghia, MD, PhD9, Gillian Corbett10*, Patricia Walker, MBBS11*, Miklos Egyed12*, Wojciech Jurczak, MD, PhD13*, Gilles A. Salles, MD, PhD14, Ann Janssens15*, Florence Cymbalista, MD, PhD16*, William G. Wierda, MD, PhD17, Steven Coutre, MD18, John M. Pagel, MD, PhD, DSc19, Alan Skarbnik, MD20,21, Manali Kamdar, MD22, Jennifer Woyach, MD23, Raquel Izumi, PhD24, Veerendra Munugalavada, PhD24, Priti Patel, MD24, Min Hui Wang, PhD24*, Sofia Wong24* and John C Byrd, MD25	31 ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)Clinically Relevant Abstract <a href="https://ash.confex.com/ash/2019/webprogram/Paper128404.html">https://ash.confex.com/ash/2019/webprogram/Paper128404.html</a>	Session 642 USOR #15061	Saturday, December 7, 2019, 7:30 AM  Hall D, Level 2 Orange County Convention Center

**Bolded text:** US Oncology Research affiliated investigator

\*Denotes non-member of the American Society of Hematology

## EDUCATION PROGRAM

Authors	Title	Session #	Date/Time/ Location
<b>Jeff P. Sharman, MD</b>	Targeting CD20: Teaching an Old Dog New Tricks <a href="https://ash.confex.com/ash/2019/webprogram/Paper121009.html">https://ash.confex.com/ash/2019/webprogram/Paper121009.html</a>		Saturday, December 7, 2019, 2:00 PM–3:30 PM Tangerine 1 (WF1), Level 2 Orange County Convention Center
			Sunday, December 8, 2019, 9:30 AM–11:00 AM Tangerine 1 (WF1), Level 2 Orange County Convention Center

**Bolded text:** US Oncology Research affiliated investigator

\*Denotes non-member of the American Society of Hematology

**To learn more, please contact**  
**[researchopportunities@mckesson.com](mailto:researchopportunities@mckesson.com)**